Petros Pharmaceuticals, Inc. (PTPI) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
PTPI Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 9, 2026, Petros Pharmaceuticals, Inc. (PTPI) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.01 and trailing twelve-month earnings per share of $-0.17.
Compared to the Healthcare sector median P/E of 21.9x, PTPI trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, PTPI trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PTPI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PTPI P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 55.4 | - | -4% | |
| $1B | 176.0 | - | -79% | |
| $896B | 41.3 | 1.43 | +96% | |
| $146B | 18.9 | - | -4% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $116B | 65.1 | - | -62% | |
| $90B | 19.2 | - | +49% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See PTPI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTPI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTPI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTPI — Frequently Asked Questions
Quick answers to the most common questions about buying PTPI stock.
Is PTPI stock overvalued or undervalued?
PTPI current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
How does PTPI's valuation compare to peers?
Petros Pharmaceuticals, Inc. P/E of -0.0x compares to sector median of 21.9x. Sector comparison provides relative valuation context.
What is PTPI's PEG ratio?
PTPI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.